tetano
Editor, Senior Moderator
Viruses
. 2021 Dec 21;14(1):8.
doi: 10.3390/v14010008.
Activity of Galidesivir in a Hamster Model of SARS-CoV-2
Ray Taylor[SUP] 1 [/SUP], Richard Bowen[SUP] 2 [/SUP], James F Demarest[SUP] 1 [/SUP], Michael DeSpirito[SUP] 1 [/SUP], Airn Hartwig[SUP] 2 [/SUP], Helle Bielefeldt-Ohmann[SUP] 3 [/SUP], Dennis M Walling[SUP] 1 [/SUP], Amanda Mathis[SUP] 1 [/SUP], Yarlagadda S Babu[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) has claimed the lives of millions of people worldwide since it first emerged. The impact of the COVID-19 pandemic on public health and the global economy has highlighted the medical need for the development of broadly acting interventions against emerging viral threats. Galidesivir is a broad-spectrum antiviral compound with demonstrated in vitro and in vivo efficacy against several RNA viruses of public health concern, including those causing yellow fever, Ebola, Marburg, and Rift Valley fever. In vitro studies have shown that the antiviral activity of galidesivir also extends to coronaviruses. Herein, we describe the efficacy of galidesivir in the Syrian golden hamster model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Treatment with galidesivir reduced lung pathology in infected animals compared with untreated controls when treatment was initiated 24 h prior to infection. These results add to the evidence of the applicability of galidesivir as a potential medical intervention for a range of acute viral illnesses, including coronaviruses.
Keywords: RNA viruses; SARS-CoV-2; antiviral; coronavirus; nucleoside analog.
. 2021 Dec 21;14(1):8.
doi: 10.3390/v14010008.
Activity of Galidesivir in a Hamster Model of SARS-CoV-2
Ray Taylor[SUP] 1 [/SUP], Richard Bowen[SUP] 2 [/SUP], James F Demarest[SUP] 1 [/SUP], Michael DeSpirito[SUP] 1 [/SUP], Airn Hartwig[SUP] 2 [/SUP], Helle Bielefeldt-Ohmann[SUP] 3 [/SUP], Dennis M Walling[SUP] 1 [/SUP], Amanda Mathis[SUP] 1 [/SUP], Yarlagadda S Babu[SUP] 1 [/SUP]
Affiliations
- PMID: 35062212
- DOI: 10.3390/v14010008
Abstract
Coronavirus disease 2019 (COVID-19) has claimed the lives of millions of people worldwide since it first emerged. The impact of the COVID-19 pandemic on public health and the global economy has highlighted the medical need for the development of broadly acting interventions against emerging viral threats. Galidesivir is a broad-spectrum antiviral compound with demonstrated in vitro and in vivo efficacy against several RNA viruses of public health concern, including those causing yellow fever, Ebola, Marburg, and Rift Valley fever. In vitro studies have shown that the antiviral activity of galidesivir also extends to coronaviruses. Herein, we describe the efficacy of galidesivir in the Syrian golden hamster model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Treatment with galidesivir reduced lung pathology in infected animals compared with untreated controls when treatment was initiated 24 h prior to infection. These results add to the evidence of the applicability of galidesivir as a potential medical intervention for a range of acute viral illnesses, including coronaviruses.
Keywords: RNA viruses; SARS-CoV-2; antiviral; coronavirus; nucleoside analog.